Tesamorelin significantly reduces abdominal fat
Tesamorelin (formerly known as TH9507), is a type of peptide called a growth hormone-releasing factor (GHRF). GHRF causes growth hormone to be created and spread in the body, which helps increase metabolism, reduce belly fat, improve body shape, and use of energy. Clinical trials have shown that tesamorelin significantly reduces abdominal fat with fewer side effects than human growth hormone itself, although abdominal fat may partially return after the Tesamorlein is discontinued (depending upon the individual).
Tesamorelin also Boosts Cognition in Elderly
Tesamorelin is a stabilized analogue of the growth hormone-releasing factor (GRF) that induces growth hormone (GH) in a specific and physiological manner. To date, clinical studies suggest that Tesamorelin reduces visceral fat in HIV-infected patients with abdominal lipo-hypertrophy as well as reducing abdominal fat in all individuals studied. A peptide that increases growth hormone release improved several measures of cognitive function in cognitively normal and mildly impaired older individuals in a placebo-controlled trial, a researcher said here. Scores on standard tests of executive function and verbal memory were significantly higher in participants given tesamorelin (Egrifta), a synthetic analog of growth hormone releasing hormone (GHRH), in a 20-week trial, according to Laura D. Baker, PhD.. Participants taking the drug in the 78-person trial also reported greater subjective improvement in cognition relative to the placebo group.
In 2006 clinical trial with GHRH found small but significant improvements in cognitive test scores in healthy older adults. In the current study, funded by the National Institute on Aging, 41 cognitively normal adults and 37 with mild cognitive impairment were randomized to placebo or tesamorelin at 1 mg/day subcutaneously. Mean participant age was 66 to 70 among the four groups. Scores on the Mini-Mental State Examination averaged 29 for the normal participants and 28 for those with mild impairments. Normal and impaired participants differed more at baseline on a test of story recall, with mean scores of 54 and 44, respectively. Tesamorelin appeared to have a protective effect relative to placebo among the cognitively impaired patients on this measure. At the final evaluation, scores declined an average of five points with placebo, whereas those assigned to tesamorelin had a mean decline of less than one point.
Tesamorelin reduces lipodystrophy
Tesamorelin has been shown to reduce lipodystrophy in individuals. Lipodystrophy is a condition that causes changes in placement of body fat, including wasting and fat accumulation, and changes in metabolism. Similar to Tesamorelin is Sermorelin, which may be taken with GHRP-6 is clinical trials, that also promotes HGH production and possible fat loss. Individuals with lipodystrophy may develop excess fat most notably around the liver, stomach, and other abdominal organs (visceral body fat).
Tesamorelin benefits and effects
- Tesamorelin significantly reduces belly fat
- Tesamorelin increases the secretion of growth hormone
- Tesamorelin can also provide other positive effects associated with elevated growth hormone levels
Tesamorelin possible side effects
- irritation at the injection site
- tingling in the hands or fingers
- swelling of the hands, ankles or feet
- Tesamorelin may cause glucose intolerance, high blood sugar or increase the risk of type 2 diabetes
Optimal dose of Tesamorelin is often reported as 2 mg of Tesamorelin once daily into the abdomen.